<DOC>
	<DOCNO>NCT00025376</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know regimen PS-341 effective treating metastatic kidney cancer . PURPOSE : Randomized phase III trial study effectiveness PS-341 treating patient metastatic kidney cancer .</brief_summary>
	<brief_title>PS-341 Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient metastatic renal cell cancer treat bortezomib . - Determine time tumor progression 1-year survival patient treated drug . - Determine toxicity profile drug patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive bortezomib IV 3-5 second twice weekly week 1 2 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients undergo core biopsy . - Arm II : Patients undergo core biopsy . Patients receive bortezomib IV arm I . Patients undergo radiologic re-evaluation measurable lesion . Patients stable disease partial complete response continue receive bortezomib absence disease progression unacceptable toxicity . Patients follow 2 year . PROJECTED ACCRUAL : A total 21-41 patient accrue study within 9-14 month .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic renal cell cancer Measurable disease At least 2.0 cm least 1 dimension physical exam OR least 1.0 cm least 1 dimension radiologic exam Single measurable lesion must within prior radiotherapy portal Tumor lesion amenable core biopsy At least 1 cm tumor obtainable No active CNS metastatic disease Single previously resect CNS metastasis allow provided disease progression 8 week therapy longer require steroid antiseizure medication PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Prior immunotherapy biotherapy allow Chemotherapy : No prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow ( i.e. , whole pelvis ) Surgery : See Disease Characteristics Other : No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>